Sangamo Therapeutics Company Leadership
| SGMO Stock | USD 1.94 0.01 0.51% |
About 80 percent of Sangamo Therapeutics' insiders are selling. The analysis of the overall insider sentiment regarding Sangamo Therapeutics suggests that quite a few insiders are terrified. Sangamo Therapeutics employs about 405 people. The company is managed by 16 executives with a total tenure of roughly 5 years, averaging almost 0.0 years of service per executive, having 25.31 employees per reported executive.
| Jason Fontenot President Senior Vice President Cell Therapy |
Sangamo Therapeutics' Insider Buying Vs Selling
20
Selling | Buying |
Latest Trades
| 2023-09-26 | Biogen Inc. | Disposed 6000000 @ 0.5 | View | ||
| 2022-08-29 | Biogen Inc. | Disposed 400000 @ 5.33 | View | ||
| 2022-06-03 | John Markels | Acquired 6784 @ 3.69 | View | ||
| 2021-12-27 | Biogen Inc. | Disposed 600 @ 8.56 | View | ||
| 2021-12-23 | Biogen Inc. | Disposed 81187 @ 8.55 | View |
Monitoring Sangamo Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Sangamo |
Sangamo Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.5829) % which means that it has lost $0.5829 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.9405) %, meaning that it created substantial loss on money invested by shareholders. Sangamo Therapeutics' management efficiency ratios could be used to measure how well Sangamo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of December 2024, Return On Tangible Assets is likely to grow to -1.48. In addition to that, Return On Capital Employed is likely to grow to -2.21. At this time, Sangamo Therapeutics' Total Assets are very stable compared to the past year. As of the 12th of December 2024, Non Currrent Assets Other is likely to grow to about 19 M, while Other Assets are likely to drop 0.95.As of the 12th of December 2024, Common Stock Shares Outstanding is likely to grow to about 183.2 M, though Net Loss is likely to grow to (164.4 M).
Sangamo Therapeutics Workforce Comparison
Sangamo Therapeutics is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 3,948. Sangamo Therapeutics retains roughly 405 in number of employees claiming about 10% of equities under Health Care industry.
Sangamo Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sangamo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sangamo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Sangamo Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Macrae Sandy over two weeks ago Disposition of 10642 shares by Macrae Sandy of Sangamo Therapeutics at 1.94 subject to Rule 16b-3 | ||
Macrae Sandy over two weeks ago Disposition of 7473 shares by Macrae Sandy of Sangamo Therapeutics at 1.88 subject to Rule 16b-3 | ||
Gregory Davis over a month ago Insider Trading | ||
Horn Margaret A over a month ago Acquisition by Horn Margaret A of 13900 shares of Sangamo Therapeutics subject to Rule 16b-3 | ||
Dubois-stringfellow Nathalie over two months ago Disposition of 5474 shares by Dubois-stringfellow Nathalie of Sangamo Therapeutics at 1.13 subject to Rule 16b-3 | ||
Scott Willoughby over three months ago Disposition of 3453 shares by Scott Willoughby of Sangamo Therapeutics at 1.13 subject to Rule 16b-3 | ||
Jason Fontenot over three months ago Disposition of 1029 shares by Jason Fontenot of Sangamo Therapeutics at 0.77 subject to Rule 16b-3 | ||
Macrae Sandy over three months ago Disposition of 7492 shares by Macrae Sandy of Sangamo Therapeutics at 0.86 subject to Rule 16b-3 |
Sangamo Therapeutics Notable Stakeholders
A Sangamo Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sangamo Therapeutics often face trade-offs trying to please all of them. Sangamo Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sangamo Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Jason Fontenot | Senior Vice President Cell Therapy | Profile | |
| Scott Willoughby | General VP | Profile | |
| Phillip Ramsey | Head Operations | Profile | |
| David Ojala | Scientist Research | Profile | |
| Mark McClung | Ex COO | Profile | |
| Stephanie CLP | Head Management | Profile | |
| Whitney Jones | VP Officer | Profile | |
| Andrew Ramelmeier | Ex Operations | Profile | |
| Gregory Davis | Head Technology | Profile | |
| Lisa MD | Chief Officer | Profile | |
| Aron Feingold | Head Officer | Profile | |
| Amy Pooler | Head Research | Profile | |
| ChB MB | Pres CEO | Profile | |
| Heather Erickson | Chief Staff | Profile | |
| Nathalie DuboisStringfellow | Senior Officer | Profile | |
| Louise Wilkie | Vice Communications | Profile |
About Sangamo Therapeutics Management Performance
The success or failure of an entity such as Sangamo Therapeutics often depends on how effective the management is. Sangamo Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sangamo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sangamo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.56) | (1.48) | |
| Return On Capital Employed | (2.33) | (2.21) | |
| Return On Assets | (1.56) | (1.48) | |
| Return On Equity | (3.11) | (2.96) |
Sangamo Therapeutics Workforce Analysis
Traditionally, organizations such as Sangamo Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sangamo Therapeutics within its industry.Sangamo Therapeutics Manpower Efficiency
Return on Sangamo Therapeutics Manpower
| Revenue Per Employee | 435.1K | |
| Revenue Per Executive | 11M | |
| Net Loss Per Employee | 636.6K | |
| Net Loss Per Executive | 16.1M | |
| Working Capital Per Employee | 115.1K | |
| Working Capital Per Executive | 2.9M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share 0.066 | Quarterly Revenue Growth (0.95) | Return On Assets (0.58) | Return On Equity (1.94) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.